文献速递糖尿病骨质疏松与钙磷/甲状旁腺

2型糖尿病合并非瓣膜性心房颤动患者使用不同口服抗凝药时骨折风险的评估

Evaluation of Fracture Risk Among Patients With Type 2 Diabetes and Nonvalvular Atrial Fibrillation Receiving Different Oral Anticoagulants.
PubMed 文献 · Diabetes Care · 2022-01-01

这项回顾性、倾向评分加权、基于人群的队列研究纳入2005至2019年香港医院管理局电子数据库中15,770例2型糖尿病合并心房颤动患者(NOAC组9,288例,华法林组6,482例)。中位随访20个月期间,551例(3.5%)发生主要骨质疏松性骨折(NOAC组201例[2.2%],华法林组350例[5.4%])。校正后NOAC组累积发生率低于华法林组(HR 0.80;95%CI 0.64, 0.99;P=0.044)。作者认为NOAC使用与较低的主要骨质疏松性骨折风险相关,从骨骼健康角度看NOAC可能是首选抗凝药。

要点

  • 中位随访20个月,NOAC组主要骨质疏松性骨折201例(2.2%),华法林组350例(5.4%)。
  • 校正后NOAC组较华法林组主要骨质疏松性骨折风险降低(HR 0.80;95%CI 0.64, 0.99;P=0.044)。
  • 作者认为从骨骼健康角度看NOAC可能是2型糖尿病合并房颤患者的首选抗凝药。

核心结论

  • 在2型糖尿病合并心房颤动患者中,NOAC使用与较华法林更低的主要骨质疏松性骨折风险相关。
  • 作者认为从骨骼健康角度看NOAC可能是首选抗凝药。

研究设计与样本

  • 回顾性、倾向评分加权、基于人群的队列研究,数据来自香港医院管理局电子数据库。
  • 纳入2005至2019年开始华法林或NOAC治疗的成人2型糖尿病合并心房颤动患者,共15,770例(NOAC组9,288例,华法林组6,482例)。
  • 主要结局为主要骨质疏松性骨折的复合终点(髋部、临床椎体、肱骨近端和腕部)。
  • 采用Cox比例风险回归模型计算风险比(HR)。

主要发现

  • 中位随访20个月,551例(3.5%)发生主要骨质疏松性骨折,其中NOAC组201例(2.2%),华法林组350例(5.4%)。
  • 校正后NOAC组累积发生率低于华法林组(HR 0.80;95%CI 0.64, 0.99;P=0.044)。
  • 亚组分析显示,在性别、年龄、HbA1c、糖尿病病程和严重低血糖史各亚组中,NOAC组较华法林组对主要骨质疏松性骨折的保护作用一致。

临床怎么用

  • 作者认为从骨骼健康角度看,NOAC可能是2型糖尿病合并心房颤动患者的首选抗凝药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with type 2 diabetes are at higher risk for fracture risk because of attenuated bone turnover and impaired bone microarchitecture. The comparative effect of warfarin over non-vitamin K antagonist oral anticoagulants (NOACs) on incident fractures among patients with type 2 diabetes comorbid with atrial fibrillation (AF) remains to be elucidated. RESEARCH DESIGN AND METHODS: This was a retrospective, propensity score-weighted, population-based cohort study of adults with type 2 diabetes and AF who were started on warfarin or NOAC between 2005 and 2019 identified from an electronic database of the Hong Kong Hospital Authority. The primary outcome was a composite of major osteoporotic fractures (hip, clinical vertebral, proximal humerus, and wrist). Hazard ratios (HRs) were calculated using Cox proportional hazards regression models. RESULTS: A total of 15,770 patients with type 2 diabetes comorbid with AF were included (9,288 on NOAC, 6,482 on warfarin). During a median follow-up of 20 months, 551 patients (3.5%) sustained major osteoporotic fractures (201 [2.2%] in the NOAC group, 350 [5.4%] in the warfarin group). The adjusted cumulative incidence was lower among NOAC users than warfarin users (HR 0.80; 95% CI 0.64, 0.99; P = 0.044). Subgroup analyses showed consistent protective effects against major osteoporotic fractures among NOAC users across sex, age, HbA1c, duration of diabetes, and history of severe hypoglycemia compared with warfarin users. CONCLUSIONS: NOAC use was associated with a lower risk of major osteoporotic fractures than warfarin use among patients with type 2 diabetes comorbid with AF. NOAC may be the preferred anticoagulant from the perspective of bone health.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lui DTW, Ho Man Tang E, Au ICH, et al. Evaluation of Fracture Risk Among Patients With Type 2 Diabetes and Nonvalvular Atrial Fibrillation Receiving Different Oral Anticoagulants. Diabetes Care. 2022. PMID: 36126158. doi:10.2337/dc22-0664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。